Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Roche acquires digital diabetes management platform

Will integrate mySugr within its new patient-centred health services arm

Roche

Roche has acquired a smartphone-based diabetes management platform and will integrated it into its new patient-centred health services in diabetes care arm.

Apps and services from mySugr combine diabetes coaching, therapy management, unlimited test-strips and automated data tracking.

They can be integrated with a number of medical devices and Roche will keep it running as an open platform for all diabetes devices and services, irrespective of their manufacturer.

But the Swiss pharma firm will be keen to demonstrate to healthcare providers the benefits of using its Accu-Chek range of tools to improve therapy decisions and improve patient communication.

Roland Diggelmann, CEO of Roche Diagnostics, said: “We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life.

“Having partnered with mySugr since 2014, we see an excellent cultural fit, as both our companies are passionate about taking diabetes management to the next level and making a difference in managing diabetes.”

Founded in 2012, mySugr GmbH has offices in San Diego and Vienna, and more than one million users globally.

Frank Westermann, mySugr’s CEO and co-founder, said: “We started mySugr to solve our everyday problems and simplify diabetes therapy through smartphones.

“The mySugr team has filled a gap for over a million loyal users so far, and with Roche’s diabetes expertise and global network, mySugr will become an indispensable companion for hassle-free life.”

Roche, which was an early investor in the platform through its Roche Venture Fund, has now acquired all shares of mySugr GmbH and plans to keep it as a separate legal entity.

Article by
Dominic Tyer

4th July 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics